ClinicalTrials.gg

Program

zorifertinib

Also written as “AZD3759” and “Zorifertinib and Osimertinib Combination Therapy”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Meningeal Carcinomatosis, led by 3 companies.

Furthest: phase 3, since Aug 22, 20184 company-led studies, 1 open or runningNext primary completion: Apr 23, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alpha Biopharma (Jiangsu)21 open or runningphase 3since Aug 22, 2018Aug 22, 2018Apr 23, 2028phase 1 · NCT07361705
AstraZeneca10 open or runningphase 1since Aug 20, 2014Aug 20, 2014none ahead
LYZZ Alpha10 open or runningphase 2since Nov 16, 2017Nov 16, 2017none ahead

Also a collaborator on its studies: Tigermed Consulting.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2014First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT02228369 · 108 enrolled · United States, Australia, Korea, Republic of and more
  2. Nov 16, 2017LYZZ Alpha’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to LYZZ AlphaLYZZ Alpha · NCT03360929 · 15 enrolled · China
  3. Aug 22, 2018Alpha Biopharma (Jiangsu)’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Alpha Biopharma (Jiangsu)Alpha Biopharma (Jiangsu) · NCT03653546 · 492 enrolled · China, Singapore, South Korea and more
  4. Dec 4, 2025Phase 1 study in Meningeal CarcinomatosisAlpha Biopharma (Jiangsu) · NCT07361705 · 42 planned · China

Ahead

  1. Apr 23, 2028Primary completion: phase 1 study in Meningeal CarcinomatosisAlpha Biopharma (Jiangsu) · NCT07361705

TargetBeta

EGFR →read by rule
“An orally available inhibitor of the epidermal growth factor receptor (EGFR), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07361705Meningeal Carcinomatosis · China1RecruitingAlpha Biopharma (Jiangsu)Apr 23, 202842
NCT03653546Carcinoma, Non-Small-Cell Lung · China, Singapore, South Korea and more3CompletedAlpha Biopharma (Jiangsu)Jul 12, 2022492
NCT03360929Carcinoma, Non-Small-Cell Lung · China2CompletedLYZZ AlphaNov 13, 202015
NCT02228369Carcinoma, Non-Small-Cell Lung · United States, Australia, Korea, Republic of and more1CompletedAstraZenecaAug 19, 2017108

How it is read

Names in the registry

  • “AZD3759”, 3 entries
  • “Zorifertinib and Osimertinib Combination Therapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.